文献速递肾癌与肾肿瘤

乳头状肾细胞癌:ARON-1研究中接受一线免疫联合治疗或酪氨酸激酶抑制剂患者的结局

Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
PubMed 文献 · Eur Urol Oncol · 2024-04-04

ARON-1项目多中心回顾性分析200例转移性乳头状肾细胞癌患者,73例接受免疫联合治疗,127例接受酪氨酸激酶抑制剂(TKI)治疗。免疫组中位无进展生存期17.4个月优于TKI组6.4个月(p<0.001),客观缓解率41% vs 27%(p=0.037),中位总生存期28.8个月 vs 22.5个月(p=0.081)。

要点

  • 免疫联合组中位无进展生存期17.4个月,TKI组6.4个月,差异有统计学意义(p<0.001)。
  • 免疫联合组客观缓解率41%,TKI组27%,差异有统计学意义(p=0.037)。
  • 中位总生存期免疫联合组28.8个月,TKI组22.5个月,差异未达统计学显著(p=0.081)。

核心结论

  • 免疫联合治疗用于转移性乳头状肾细胞癌一线治疗,疗效结局优于酪氨酸激酶抑制剂。

研究设计与样本

  • ARON-1项目(NCT05287464)的多中心回顾性真实世界数据分析,纳入12个国家40个中心接受治疗的晚期乳头状肾细胞癌患者200例,其中73例接受免疫联合治疗,127例接受酪氨酸激酶抑制剂治疗。

主要发现

  • 中位总生存期TKI组22.5个月 vs 免疫联合组28.8个月(p=0.081)。
  • 中位无进展生存期TKI组6.4个月 vs 免疫联合组17.4个月(p<0.001)。
  • 客观缓解率TKI组27% vs 免疫联合组41%(p=0.037)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Papillary renal cell carcinoma (pRCC) is the most frequent histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of nccRCC, patients are often excluded from large phase 3 trials focused on clear cell RCC, so treatment options for nccRCC remain limited. Our aim was to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO)-based combinations in patients with pRCC. METHODS: We performed a multicenter retrospective analysis of real-world data collected for patients with advanced pRCC treated in 40 centers in 12 countries as part of the ARON-1 project (NCT05287464). The primary endpoints were overall survival (OS), progression-free survival (PFS), the overall response rate (ORR), and time to second progression (PFS2). OS, PFS, and PFS2 were estimated using the Kaplan-Meier method and results were compared between the treatment groups using a log-rank test. Univariate and multivariable analyses were carried out using Cox proportional-hazard models. KEY FINDINGS AND LIMITATIONS: We included 200 patients with metastatic pRCC, of whom 73 were treated with IO-based combinations and 127 with TKIs. Median OS was 22.5 mo in the TKI group 28.8 mo in the IO group (p = 0.081). Median PFS was 6.4 mo in the TKI group and 17.4 mo in the IO group (p < 0.001). The ORR was higher in the IO group than in the TKI group (41% vs 27%; p = 0.037). CONCLUSIONS AND CLINICAL IMPLICATIONS: Our results show that IO-based combinations have superior efficacy outcomes to TKIs for first-line treatment of metastatic pRCC. PATIENT SUMMARY: The ARON-1 project collects clinical data for patients with kidney cancer treated in multiple centers worldwide to assess outcomes in the real-world setting. We analyzed data for patients with metastatic kidney cancer of a specific subtype to evaluate the efficacy of different first-line treatments. Patients treated with immune-based combinations had better outcomes than patients treated with tyrosine kinase inhibitors.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Massari F, Mollica V, Fiala O, et al. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study. Eur Urol Oncol. 2024. PMID: 38575409. doi:10.1016/j.euo.2024.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。